Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of subcutaneous sonelokimab in biologic-naive adults with active psoriatic arthritis
2024-516213-20-00Phase 3Authorised
- Sponsor
- MoonLake Immunotherapeutics
- Start
- Mar 2025
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial of sonelokimab in psoriatic arthritis (PsA) and plaque psoriasis (3 arms), sponsored by MoonLake Immunotherapeutics. Primary endpoint: ACR50 response at Week 16. Planned start Mar 2025; status: authorised.
02
Drugs
sonelokimab
03
Conditions
psoriatic arthritis (PsA)plaque psoriasis
Beyond the preview
Go deeper on 2024-516213-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516213-20-00.